Sleep disorders

Identify and guide treatment for type 1 narcolepsy

For individuals affected by narcolepsy, analysis of orexin, a neuropeptide produced in the hypothalamus and involved in the sleep/wake cycle, can help establish diagnosis. Impairment of orexin production and orexin-modulated neurotransmission is associated with narcolepsy with cataplexy, and an abnormally low concentration of orexin-A/hypocretin-1 in cerebrospinal fluid (CSF) is indicative of type 1 narcolepsy. Determining orexin-A/hypocretin-1 levels through CSF testing provides a sensitive and specific result to guide appropriate treatment for patients.

Sleep disorders Test menu

Sleep disorders

Key testing


  • Aids in the diagnosis and differentiation of type 1 narcolepsy from other causes of hypersomnolence.
  • Especially helpful for patients suspected of narcolepsy for whom a multiple sleep latency test (MSLT) is difficult to interpret due to shift work, lack of sleep, confounding medications, or the presence of untreated or partially treated sleep apnea. It can also be helpful in patient of a young age for whom MSLT is not valid on its own.


  1. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 2008 Jul;7(7):649-662. doi:10.1016/S1474-4422(08)70140-6

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.